Emerging drug treatments for cystic fibrosis (Q57952080)

Expert Opinion on Emerging Drugs

Europe PubMed Central

title

Emerging drug treatments for cystic fibrosis (English)

0 references

1 reference

Pamela L Zeitlin

1

0 references

language of work or name

English

0 references

publication date

May 2007

0 references

published in

0 references

volume

12

0 references

page(s)

329-336

0 references

issue

2

0 references

cites work

Emerging drug treatments for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Magainins: a new family of membrane-active host defense peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Antimicrobial activity of synthetic magainin peptides and several analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Standards of care for patients with cystic fibrosis: a European consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Patterns of medical practice in cystic fibrosis: part I. Evaluation and monitoring of health status of patients. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

A phase I trial of intranasal Moli1901 for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Pulmonary mucus: Pediatric perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Hyperosmolar agents and clearance of mucus in the diseased airway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Inhaled heparin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

A new model of cystic fibrosis pathology: lack of transport of glutathione and its thiocyanate conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

CFTR directly mediates nucleotide-regulated glutathione flux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Activation of chloride transport in CF airway epithelial cell lines and primary CF nasal epithelial cells by S-nitrosoglutathione.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Increased arginase activity in cystic fibrosis airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Inositol polyphosphate derivative inhibits Na+ transport and improves fluid dynamics in cystic fibrosis airway epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329

Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.329